9th Asia Agri-Tech Expo & Forum Opens Today, Driving Innovation in Asia-Pacific Agriculture
TAIPEI, June 11, 2025 /PRNewswire/ -- Organised by Informa Markets Asia Ltd., the 2025 Asia Agri-Tech Expo & Forum officially opened today (June 11) at the ICC Tainan. The grand opening ceremony gathered key representatives from government, industry, academia, and research to witness a new milestone in the advancement of agri-tech in the Asia-Pacific region.
Distinguished guests attending the ribbon-cutting ceremony included Mr. Michael Duck, Executive Vice President of Informa Markets Asia, Deputy Mayor Yeh Tse-Shan of Tainan City Government, President Su Chih-Fen of the National Animal Industry Foundation, along with numerous prominent figures from various sectors.
This year's event features over 150 exhibitors from around the world, showcasing cutting-edge innovations in agriculture automation, smart livestock farming, precision irrigation, crop monitoring, and feed technology. In addition to the exhibition, the event presents 10 key themes across 60 professional seminars, offering in-depth discussions on emerging trends in agriculture, smart livestock farming, advanced feed technology, and biosecurity upgrades.
The three-day exhibition is expected to attract over 25,000 visitors. With Tainan serving as a central hub for agriculture and aquaculture in southern Taiwan, the event provides an ideal platform for farmers, growers, and industry professionals to explore the latest advancements. Many exhibitors are launching new products on-site, including:
TOTAL NUTRITION: Combining peptide protein, probiotics, and acidifiers to form the "Golden Triangle" of gut health, achieving precise nutritional regulation and enhanced well-being.
WONDER VAX: Introducing the Universal Live Vaccine for Infectious Bronchitis in Chickens (TW-I, TW-II), providing dual protection against respiratory and nephritis strains, precisely targeting Taiwan's prevalent local strains (TW-I, TW-II).
YA SUH DAR: Launching a 50-inch butterfly shutter exhaust fan specifically designed for livestock farming. This large negative-pressure fan features an innovative pneumatic butterfly shutter design that effectively replaces traditional louver windows, significantly improving ventilation efficiency. It also offers excellent dustproof, corrosion-resistant, and weather-resistant performance, making it ideal for harsh environments with high temperatures and humidity.
VETNOSTRUM: Comprehensive range of veterinary medicines, health products, feed additives, and feeds for pigs, cattle, sheep, poultry, and aquatic animals.
AGRISTAR: Asia's first fully electric tractor, manufactured by Foxconn in the U.S., featuring Tesla technology and NVIDIA AI computing. Compatible with a variety of agricultural implements, it serves not only in dairy farming but also in a wide range of daily agricultural and livestock operations. This next-generation farming equipment paves the way for a net-zero carbon, sustainable agricultural future.
Ms. Grace Lee, General Manager of Informa Markets Taiwan, stated: "Taiwan's agricultural sector boasts strong technological capabilities. Through this international platform, we foster knowledge exchange and drive innovation, enhancing global food self-sufficiency where Taiwan will play an increasingly pivotal role."
The expo runs from June 11 to 13, open to industry professionals and related personnel free of charge. The organizers aim to foster cross-border collaboration and create a prosperous future for Asia-Pacific agriculture, paving the way for the next century of agricultural innovation.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/9th-asia-agri-tech-expo--forum-opens-today-driving-innovation-in-asia-pacific-agriculture-302478726.html
SOURCE Informa Markets Asia Ltd., Taiwan Branch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled "BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy" in the New England Journal of Medicine (NEJM), which has reported for the first time globally the research data on a BCMA x CD3 bispecific antibody treatment for patients with refractory autoimmune hemolytic anemia (AIHA). The study results showed that two patients experienced rapid disease improvement after the administration of CM336, achieving partial remission on days 13 and 19, respectively. Hemoglobin levels returned to normal on days 17 and 21, respectively, while reticulocyte counts, lactate dehydrogenase, and indirect bilirubin levels significantly decreased. Before receiving treatment with CM336, both patients had undergone multiple treatment regimens, including glucocorticoids, splenectomy, anti-CD20 antibodies, BTK inhibitors, and CD19 CAR-T cell therapies, but their disease eventually recurred or progressed to refractory status. The latest assessment results after 6 months post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period. The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with relapsed/refractory AIHA who had previously received multiple therapies, with rapid disease control and sustained remission lasting over half a year, while also exhibiting good safety profile, potentially making it an innovative treatment option for development in this disease. About CM336CM336 is a BCMA x CD3 bispecific antibody that can simultaneously target and identify and specifically bind both BCMA on the surface of target cells and the CD3 receptors on the surface of T cells to recruit immune T cells to the vicinity of the target cells, thereby inducing T-cell dependent cellular cytotoxicity (TDCC) to eliminate the target cells. As of the date of this announcement, the Phase II clinical study of CM336 for the treatment of primary light-chain amyloidosis has been approved by the Center for Drug Evaluation of the National Medical Products Administration and will commence clinical trials shortly. About Keymed BiosciencesKeymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. View original content: SOURCE Keymed Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
(Reuters) -AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
Yahoo
an hour ago
- Yahoo
Images show new North Korea uranium enrichment plant, analysts say
THE HAGUE, Netherlands — North Korea appears to be expanding its nuclear program through the addition of a purpose-built enrichment facility, satellite images show. The blue-roofed building, 93 meters long and 28 meters wide, may house several thousand centrifuges used to enrich uranium isotopes to weapons-grade material once completed. It is visually almost identical to similar facilities that North Korea already operates and that have provided the uranium for the country's six nuclear tests and growing arsenal of atomic bombs. The facility has been referenced by the UN system's nuclear watchdog, the International Atomic Energy Agency, although it has not yet released any images or extensive public information. 'The Agency is monitoring the construction of a new building at Yongbyon, which has dimensions and features similar to the Kangson enrichment plant,' the IAEA's director general, Rafael Mariano Grossi, told the organization's Board of Governors on June 9. Researchers from the James Martin Center for Nonproliferation, based in Monterey, California, have been the first to publicly identify the site and released annotated satellite images of the location. Using commercial satellite imagery, Defense News has been able to determine that construction on the new building started in mid-February of this year. According to the California-based experts' accompanying estimates, the facility, located close to North Korea's premier nuclear research complex, would be able to add anywhere from 70 to nearly 100 kilograms of highly enriched uranium to Pyongyang's stockpile annually. This would likely suffice for five to ten new warheads a year, based on commonly cited estimates of ten to 20 kilograms of HEU needed for an implosion-type nuclear weapon. More advanced weapons might need less. 'We are starting to see a scaling up of the North Korean nuclear program, probably to achieve some sort of desired arsenal size,' said Sam Lair, one of the researchers at the Center for Nonproliferation Studies involved in revealing the facility. North Korea is estimated by researchers to already operate three enrichment facilities, two of which have been additionally expanded with annexes housing yet more centrifuges. Collectively, the existing sites are estimated to house over 10,000 centrifuges that produce more than 200 kilograms of weapons-grade uranium-235 every year. 'The message is clear: The North Korean nuclear program is here to stay,' said Lair, who also pointed out that Pyongyang's state media had released unprecedented footage from Kim Jong-Un, North Korea's leader, visiting the inside of two other enrichment plants in recent months. It was the first time North Korea published any imagery of these facilities. 'They want to show that these are large, real facilities and they won't be bargained away in some sort of an agreement, like what the first Trump administration pursued,' Lair said. It may also send important messages to domestic audiences about Kim Jong-Un's contribution to keeping his country – and its elite – safe from any foreign military intervention by developing its nuclear program. North Korea has emerged as an aggressive nuclear player. The country conducted its first test in late 2006, after years of an international standoff surrounding its nuclear program. The country left the global Treaty on the Non-Proliferation of Nuclear Weapons in 2003, which still counts 191 members, including all permanent members of the Security Council.
